West Pharmaceutical Services, Inc. WST
NYSE · Healthcare · Medical - Instruments & Supplies
$390.30
Close on Fri, 20 Nov 2026 · market value $27.2B
What the price is betting on
Priced for a lot to go rightAt $390, the price assumes revenue grows about 28% a year for five years, from $3.4B to about $9.7B by FY2030. That is about five times what analysts expect for the next two years and about five times the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 9.5% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than WST? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$112
Base
$129
Bull
$148
Today $390
- Bear $112. Cash flow grows 4% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $129. Cash flow grows 7% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $148. Cash flow grows 9% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$3.6B$3.4B, below the path
- FY2027$4.6B$3.6B, below the path
- FY2028$5.9B$3.9B, below the path
- FY2029$7.6B$4.2B, below the path
- FY2030$9.7B$4.4B, below the path
Each year's revenue at 28% growth from $3.4B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Instruments & Supplies · listed on NYSE
- Revenue, FY2025
- $3.1B
- Growth, 3 years a year
- 5.2%
- Cash margin
- 15%
- Net cash
- $375M
- Shares, 3-year change
- −4.1%
- Dividend yield
- 0.2%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.